NCT04939272进行中（未招募）1 期
A Phase 1/2 Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Mantle Cell Lymphoma
City of Hope Medical Center2 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2022年6月29日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 8
- 试验地点
- 2
- 主要终点
- Overall response rate (Phase II)
研究概览
简要总结
This phase I/II trial studies the side effects, best dose, and effectiveness of copanlisib and venetoclax in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Copanlisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving copanlisib and venetoclax may help treat patients with mantle cell lymphoma.
详细描述
PRIMARY OBJECTIVES:
I. To assess the safety, tolerability, and the maximum tolerated dose (MTD) of copanlisib hydrochloride (copanlisib) and venetoclax in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). (Phase 1) II. To estimate the efficacy (as measured by overall rate of response [ORR]) of copanlisib in combination with venetoclax in patients with R/R MCL. (Phase 2)
SECONDARY OBJECTIVES:
I. To characterize the safety profile of copanlisib in combination with venetoclax in patients with R/R MCL. (Phase 2) II. To evaluate duration of response (DOR) and progression-free survival (PFS) associated with combined administration of copanlisib/venetoclax. (Phase 2) III. To evaluate an overall survival (OS) associated with combined administration of copanlisib/venetoclax. (Phase 2) IV. To characterize the pharmacokinetics (PK) profile of copanlisib and venetoclax. (Phase 2)
EXPLORATORY OBJECTIVES:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented informed consent of the participant and/or legally authorized representative
- •Assent, when appropriate, will be obtained per institutional guidelines
- •Agreement to allow the use of archival tissue from diagnostic tumor biopsies
- •If unavailable, exceptions may be granted with study principal investigator (PI) approval
- •Age: >= 18 years
- •Eastern Cooperative Oncology Group (ECOG) =< 2
- •Life expectancy >= 3 months (per physician assessment)
- •Ability to take oral medication
- •Pathologically confirmed MCL, with documentation of monoclonal B cells showing one of the following:
- •Overexpression of cyclin D1 in association with other relevant markers (e.g., CD19, CD20, PAX5, CD5), OR
- •Chromosomal translocation t(11;14)(q13; q32), as assessed by cytogenetics, fluorescent in situ hybridization (FISH), or polymerase chain reaction (PCR)
- •Documented failure to achieve at least partial response (PR) with, or documented disease progression after the most recent treatment regimen
- •At least 1 prior treatment regimen for MCL which either included chemo-immunotherapy or a targeted agent (i.e., ibrutinib) administered for at least 2 cycles
- •Have radiologically measurable lymphadenopathy or extranodal lesion, (defined as >= 1 lesion that measures >= 2.0 cm in the longest diameter), or splenomegaly, or bone marrow involvement with or without malignant lymphocytosis
- •Absolute neutrophil count (ANC) >= 1,000/mm^3 without bone marrow involvement or ANC >= 500/mm^3 with bone marrow involvement (to be performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)
- •Platelets >= 50,000/mm^3 without bone marrow involvement or platelets >= 30,000/mm^3 with bone marrow involvement (to be performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)
- •NOTE: Platelet transfusions are not permitted within 7 days of platelet assessment
- •Total bilirubin =< 2 x upper limit of normal (ULN) (unless has Gilbert's disease or documented liver/biliary involvement by the lymphoma) (to be performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)
- •Aspartate aminotransferase (AST) =< 2.5 x ULN (to be performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)
- •Alanine aminotransferase (ALT) =< 2.5 x ULN (to be performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)
- •Creatinine clearance of >= 30 mL/min per 24 hour urine test or the Cockcroft-Gault formula (to be performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)
- •If not receiving anticoagulants: International normalized ratio (INR) OR prothrombin time (PT) =< 1.5 x ULN (to be performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)
- •If on anticoagulant therapy: PT must be within therapeutic range of intended use of anticoagulants (to be performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)
- •If not receiving anticoagulants: Activated partial thromboplastin time (aPTT) =< 1.5 x ULN (to be performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)
- •If on anticoagulant therapy: aPTT must be within therapeutic range of intended use of anticoagulants (to be performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)
- •Left ventricular ejection fraction (LVEF) >= 45% (to be performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)
- •Note: To be performed within 28 days prior to day 1 of protocol therapy
- •Seronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo, hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative) (to be performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)
- •If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed
- •Meets other institutional and federal requirements for infectious disease titer requirements (to be performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)
- •Note Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy
- •Lipase =< 1.5 ULN (to be performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)
- •Glycosylated hemoglobin (HbA1c) =< 8.5% (to be performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)
- •Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (to be performed within 30 days prior to day 1 of protocol therapy unless otherwise stated)
- •If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
- •Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 30 days after the last dose of protocol therapy
- •Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only) without an alternative medical cause.
排除标准
- •Concurrent enrollment in another therapeutic investigational study
- •Prior treatment with venetoclax (or other investigational small molecule BCL2 inhibitors) or with copanlisib
- •Prior allogeneic stem cell transplant
- •Prior therapeutic intervention with any of the following:
- •Therapeutic anticancer antibodies within 2 weeks
- •Radio- or toxin-immunoconjugates within 10 weeks
- •All other chemotherapy, radiation therapy within 30 days prior to initiation of therapy
- •Targeted therapy within 6 half-lives
- •Vaccinated with live vaccines within 4 weeks of the first dose of study drug
- •Systemic continuous corticosteroid therapy at a daily dose higher than 20 mg prednisone or equivalent is not allowed. Participants may be using topical or inhaled corticosteroids
- •Concurrent administration of medications or food that are strong inhibitors or inducers of CYP3A4 taken within 7 days of starting study treatment
- •Current evidence of central nervous system involvement by the lymphoma
- •Uncontrolled active systemic infection
- •Unresolved toxicities (except alopecia) from prior anticancer therapy (including radiation) that have not resolved to grade =< 1 (per Common Terminology Criteria for Adverse Events [CTCAE] version [v] 5.0), or to the levels dictated in this protocol
- •Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection
- •Participants who are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) result before enrollment. Those who are PCR positive will be excluded
- •History of prior malignancy except:
- •Malignancy treated with curative intent and no known active disease present for >= 2 years prior to initiation of therapy on current study
- •Adequately treated non-melanoma skin cancer or lentigo maligna (melanoma in situ) without evidence of disease
- •Adequately treated in situ carcinomas (e.g., breast, cervical, esophageal, etc.) without evidence of disease
- •Asymptomatic prostate cancer managed with "watch and wait" strategy or hormonal therapy
- •Major surgery within 4 weeks of the first dose of study drug
- •Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months of screening
- •Uncontrolled arterial hypertension despite optimal medical management
- •History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function, such as patients requiring oxygen supplementation
- •Uncontrolled diabetes mellitus despite optimal medical management (per investigator's opinion)
- •Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks) within 3 months before the start of study medication
- •Known hypersensitivity to any of the test drugs, test drug classes, or excipients in the formulation
- •Females only: Pregnant or breastfeeding
- •Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
- •Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
研究组 & 干预措施
Treatment (copanlisib hydrochloride, venetoclax)
Experimental
Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15, and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. Copanlisib will be given at 30mg, 45mg, or 60 mg depending on the assigned dose level. Venetoclax will have a weekly dose ramp up from 20mg, 50mg, 100mg, 200mg, and then 400mg thereafter.
干预措施: Copanlisib Hydrochloride (Drug)
Treatment (copanlisib hydrochloride, venetoclax)
Experimental
Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15, and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. Copanlisib will be given at 30mg, 45mg, or 60 mg depending on the assigned dose level. Venetoclax will have a weekly dose ramp up from 20mg, 50mg, 100mg, 200mg, and then 400mg thereafter.
干预措施: Venetoclax (Drug)
结局指标
主要结局
Overall response rate (Phase II)
时间窗: Up to 2 years
Defined as the proportion of response-evaluable participants that achieve a best response of either complete response (CR) or partial response (PR) during protocol therapy. Will be estimated along with the 2-sided 95% exact binomial confidence interval.
Incidence of dose limiting toxicities (Phase I)
时间窗: Up to end of cycle 2 (1 cycle = 28 days)
Toxicities will be assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
次要结局
- Duration of response(Time from the first achievement of PR or CR to time of progressive disease, start of non-protocol anti-lymphoma therapy, or death, whichever earlier, assessed up to 2 years)
- Progression-free survival(From start of protocol treatment to time of disease relapse/progression, or death due to any cause, whichever occurs earlier, assessed up to 2 years)
- Incidence of adverse events(Up to 90 days after completion of treatment)
- Overall survival(From start of protocol treatment to time of death due to any cause, assessed up to 2 years)
- Plasma pharmacokinetics (PK) of copanlisib (Cmax)(From 30 minute before Copanlisib on cycle 2 day 15 through 24 hours after (Each cycle is 28 days))
- Plasma pharmacokinetics (PK) of copanlisib (AUC)(From 30 minute before Copanlisib on cycle 2 day 15 through 24 hours after.(Each cycle is 28 days))
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
Copanlisib Plus Venetoclax in R/R DLBCLDiffuse Large B Cell LymphomaRelapsed Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaNCT04572763Dana-Farber Cancer Institute48
终止
1 期
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast CancerAnatomic Stage IV Breast Cancer AJCC v8HER2-Positive Breast CarcinomaMetastatic Breast CarcinomaNCT04108858National Cancer Institute (NCI)2
撤回
1 期
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast CancerAnatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Malignant Neoplasm in the BrainPrognostic Stage IV Breast Cancer AJCC v8NCT03803761National Cancer Institute (NCI)
终止
1 期
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast CancerEstrogen Receptor PositiveHER2/Neu NegativeInvasive Breast CarcinomaMultifocal Breast CarcinomaPostmenopausalProgesterone Receptor PositiveStage I Breast CancerStage IA Breast CancerStage IB Breast CancerStage II Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage III Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast CancerNCT03128619Jonsson Comprehensive Cancer Center10
进行中（未招募）
1 期
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and LymphomaMetastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmLymphomaNCT03502733National Cancer Institute (NCI)64